| 唐玫琴,涂传清,田发青,李举亨,蒋剑,成小慧.沙利度胺联合VAD方案治疗老年多发性骨髓瘤患者的临床效果[J].实用中西医结合临床,2018,18(10): |
| 沙利度胺联合VAD方案治疗老年多发性骨髓瘤患者的临床效果 |
| Effect study of Thalidomide plus VAD in the treatment of multiple myeloma |
| 投稿时间：2018-08-07 修订日期：2018-08-14 |
| DOI： |
| 中文关键词: 不良反应 沙利度胺 老年多发性骨髓瘤 VAD |
| 英文关键词: adverse reactions Thalidomide multiple myeloma VAD |
| 基金项目: |
|
| 摘要点击次数: 611 |
| 全文下载次数: 206 |
| 中文摘要: |
| 【】 目的 研究老年多发性骨髓瘤患者采取沙利度胺与VAD治疗的临床价值。方法 选择我院和深圳市宝安区人民医院2008年12月-2017年4月纳入的60例老年多发性骨髓瘤患者,按照随机数字法分为研究组与对照组各30例,研究组采取沙利度胺与VAD,对照组采取VAD,对比两组临床治疗效果。结果 研究组总有效率90.00%高于对照组76.67%(P＜0.05)；两组治疗前相关指标变化情况比较,差异无统计学意义(P>0.05),研究组治疗后的β2-微球蛋白、M蛋白、骨髓瘤细胞水平低于对照组,血红蛋白水平高于对照组(P＜0.05)；两组治疗前的生活质量水平比较,差异无统计学意义(P>0.05),研究组治疗后的环境因素、躯体状况、心理健康以及社会关系评分高于对照组(P＜0.05)；研究组不良反应发生率10.00%低于对照组26.67%(P＜0.05)。结论 老年多发性骨髓瘤患者采取沙利度胺与VAD治疗效果显著,明显改善相关指标水平,提高生活质量,减少不良反应发生率,安全性高。 |
| 英文摘要: |
| Objective: To study the clinical value of Thalidomide plus VAD (Vincristine+ Adriamycin+ Dexamethasone) in elderly patients with multiple myeloma. Methods: 60 elderly patients with multiple myeloma treated from December 2008 to April 2017 in our hospital and The People’s Hospital Of Bao’An District were selected. The subjects were randomly assigned to research group and control group, 30 cases each group. Patients took the Thalidomide plus VAD or VAD alone, respectively. The therapeutic effect was probed. Results: The total effective rate in the research group (90.00%) was higher than control group (76.67%) (P＜0.05); before treatment, the related indicators for two groups were not significantly different (P＞0.05); after treatment, the values of β2-microglobulin, M protein and myeloma cell levels in the research group were lower than control group; meanwhile, the hemoglobin levels in the research group were higher than control group (P＜0.05); before treatment, the life quality for two groups was not significantly different (P＞0.05); after treatment, the scores of environment factors, physical state, mental health and social relations in the research group were higher than control group, with significant differences among groups (P＜0.05); the adverse event rate in the study group (10.00%) was lower than control group (26.67%) (P＜0.05).Conclusion: The Thalidomide plus VAD can remarkably improve the related indicators and life quality, decrease the adverse event rate and increase the clinical safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
